Use of Rituximab in Opsoclonus-Myoclonus in Children With Neuroblastoma

Summary

The purpose of this study is to evaluate the feasibility of giving four weekly doses of Rituximab (anti-CD20 antibody) in the treatment of children with refractory neuroblastoma associated opsoclonus-myoclonus. Patients must have continued symptoms of opsoclonus, myoclonus and or ataxia despite surgical resection and a minimum of one month of steroid therapy. Evaluations include clinical symptoms of opsoclonus-myoclonus and ataxia as well as detailed evaluation of learning and development.

Timeline

Start

2005-07

Primary completion

2008-12

Completion

2009-02-05

Outcome

Outcome not reported

Stopped (Enrollment): “Closed early due to low accrual.”

Drugs

Indications